miR‑142‑3p reduces the viability of human cervical cancer cells by negatively regulating the cytoplasmic localization of HMGB1

Dong,Hui; Song,Jie

doi:10.3892/etm.2021.9644

miR‑142‑3p reduces the viability of human cervical cancer cells by negatively regulating the cytoplasmic localization of HMGB1

Authors:
- Hui Dong
- Jie Song
View Affiliations

Affiliations: Department of Obstetrics, Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin 300052, P.R. China, Department of Gynecology, Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin 300052, P.R. China
Published online on: January 14, 2021 https://doi.org/10.3892/etm.2021.9644
Article Number: 212
Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High mobility group protein B1 (HMGB1) is a nuclear protein that has been reported to contribute to tumor growth in humans. The present study identified a microRNA (miR/miRNA) that targets the 3' untranslated region (3'UTR) of the HMGB1 gene and assessed its effects on the proliferation of human cervical cancer cells and associated molecular mechanism. Western blotting was performed to determine HMGB1 levels in HeLa cells. TargetScan software was used to identify miRNA binding sites adjacent to the HMGB1. The viability of HeLa cells transfected with miR‑142‑3p mimics or inhibitors was determined using an MTT assay. The subcellular distribution (cytoplasmic or nuclear) of HMGB1 in HeLa cells was observed by western blotting. HMGB1 expression in HeLa and CaSKi cells was significantly higher compared with normal control cervical cells. TargetScan analysis indicated that miR‑142‑3p binds to the 3'UTR of HMGB1. Transfection with a miR‑142‑3p inhibitor increased cytoplasmic HMGB1 expression in HeLa cells, as shown by western blot analysis, while transfection with miR‑142‑3p mimics decreased the cytoplasmic expression of HMGB1 in HeLa cells. Therefore, miR‑142‑3p negatively regulated HMGB1 levels in cervical cancer cells. These findings indicated that miR‑142‑3p inhibited the proliferation of human cervical cancer cells, at least in part, by negatively regulating the cytoplasmic localization of HMGB1.

View Figures

View References

1	Wang K, Shan S, Wang S, Gu X, Zhou X and Ren T: HMGB1-containing nucleosome mediates chemotherapy-induced metastasis of human lung cancer. Biochem Biophys Res Commun. 500:758–764. 2018.PubMed/NCBI View Article : Google Scholar
2	Kumari T and Kumar B: High-mobility group box 1 protein (HMGB1) gene polymorphisms and cancer susceptibility: A comprehensive meta-analysis. Clin Chim Acta. 483:170–182. 2018.PubMed/NCBI View Article : Google Scholar
3	Osmanov T, Ugrinova I and Pasheva E: The chaperone like function of the nonhistone protein HMGB1. Biochem Biophys Res Commun. 432:231–235. 2013.PubMed/NCBI View Article : Google Scholar
4	Kang R, Xie Y, Zhang Q, Hou W, Jiang Q, Zhu S, Liu J, Zeng D, Wang H, Bartlett DL, et al: Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Res. 27:916–932. 2017.PubMed/NCBI View Article : Google Scholar
5	Yang L, Wang F, Yang L, Yuan Y, Chen Y, Zhang G and Fan Z: HMGB1 a-box reverses brain edema and deterioration of neurological function in a traumatic brain injury mouse model. Cell Physiol Biochem. 46:2532–2542. 2018.PubMed/NCBI View Article : Google Scholar
6	Ying S, Xiao X, Chen T and Lou J: PPAR ligands function as suppressors that target biological actions of HMGB1. PPAR Res. 2016(2612743)2016.PubMed/NCBI View Article : Google Scholar
7	Wu L and Yang L: The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications. Oncol Lett. 15:6799–6805. 2018.PubMed/NCBI View Article : Google Scholar
8	Huang BF, Tzeng HE, Chen PC, Wang CQ, Su CM, Wang Y, Hu GN, Zhao YM, Wang Q and Tang CH: HMGB1 genetic polymorphisms are biomarkers for the development and progression of breast cancer. Int J Med Sci. 15:580–586. 2018.PubMed/NCBI View Article : Google Scholar
9	Exner R, Sachet M, Arnold T, Zinn-Zinnenburg M, Michlmayr A, Dubsky P, Bartsch R, Steger G, Gnant M, Bergmann M, et al: Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy. Cancer Med. 5:2350–2358. 2016.PubMed/NCBI View Article : Google Scholar
10	Zhang CC, Gdynia G, Ehemann V and Roth W: The HMGB1 protein sensitizes colon carcinoma cells to cell death triggered by pro-apoptotic agents. Int J Oncol. 46:667–676. 2015.PubMed/NCBI View Article : Google Scholar
11	Yadav SS, Kumar M, Varshney A and Yadava PK: KLF4 sensitizes the colon cancer cell HCT-15 to cisplatin by altering the expression of HMGB1 and hTERT. Life Sci. 220:169–176. 2019.PubMed/NCBI View Article : Google Scholar
12	Xie B, Cao K, Li J, Chen J, Tang J, Chen X, Xia K, Zhou X, Cheng Y, Zhou J, et al: Hmgb1 inhibits Klotho expression and malignant phenotype in melanoma cells by activating NF-κB. Oncotarget. 7:80765–80782. 2016.PubMed/NCBI View Article : Google Scholar
13	Parodi M, Pedrazzi M, Cantoni C, Averna M, Patrone M, Cavaletto M, Spertino S, Pende D, Balsamo M, Pietra G, et al: Natural killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic high mobility group box-1 (HMGB1) capable of amplifying NK cell recruitment. OncoImmunology. 4(e1052353)2015.PubMed/NCBI View Article : Google Scholar
14	Zhou LY, Shi LY and Xiao Y: Changes of HMGB1 expression on angiogenesis of ovarian cancer and its mechanism. J Biol Regul Homeost Agents. 30:233–238. 2016.PubMed/NCBI
15	Wu Q, Meng WY, Jie Y and Zhao H: LncRNA MALAT1 induces colon cancer development by regulating miR-129-5p/HMGB1 axis. J Cell Physiol. 233:6750–6757. 2018.PubMed/NCBI View Article : Google Scholar
16	Chen J and Li G: MiR-1284 enhances sensitivity of cervical cancer cells to cisplatin via downregulating HMGB1. Biomed Pharmacother. 107:997–1003. 2018.PubMed/NCBI View Article : Google Scholar
17	Wu H and Zhou C: Long non-coding RNA UCA1 promotes lung cancer cell proliferation and migration via microRNA-193a/HMGB1 axis. Biochem Biophys Res Commun. 496:738–745. 2018.PubMed/NCBI View Article : Google Scholar
18	Gao H, Gong N, Ma Z, Miao X, Chen J, Cao Y and Zhang G: LncRNA ZEB2-AS1 promotes pancreatic cancer cell growth and invasion through regulating the miR-204/HMGB1 axis. Int J Biol Macromol. 116:545–551. 2018.PubMed/NCBI View Article : Google Scholar
19	Chen X, Liu X, He B, Pan Y, Sun H, Xu T, Hu X and Wang S: MiR-216b functions as a tumor suppressor by targeting HMGB1-mediated JAK2/STAT3 signaling way in colorectal cancer. Am J Cancer Res. 7:2051–2069. 2017.PubMed/NCBI
20	Wu D, Liu J, Chen J, He H, Ma H and Lv X: miR-449a suppresses tumor growth, migration, and invasion in non-small cell lung cancer by targeting a HMGB1-mediated NF-κB signaling pathway. Oncol Res. 27:227–235. 2019.PubMed/NCBI View Article : Google Scholar
21	Lv S and Guan M: miRNA-1284, a regulator of HMGB1, inhibits cell proliferation and migration in osteosarcoma. Biosci Rep. 38(BSR20171675)2018.PubMed/NCBI View Article : Google Scholar
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
23	He R, Yang L, Lin X, Chen X, Lin X, Wei F, Liang X, Luo Y, Wu Y, Gan T, et al: MiR-30a-5p suppresses cell growth and enhances apoptosis of hepatocellular carcinoma cells via targeting AEG-1. Int J Clin Exp Pathol. 8:15632–15641. 2015.PubMed/NCBI
24	Liu K, Huang J, Ni J, Song D, Ding M, Wang J, Huang X and Li W: MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p. Cell Cycle. 16:578–587. 2017.PubMed/NCBI View Article : Google Scholar
25	Li X, Wang S, Chen Y, Liu G and Yang X: miR-22 targets the 3'UTR of HMGB1 and inhibits the HMGB1-associated autophagy in osteosarcoma cells during chemotherapy. Tumour Biol. 35:6021–6028. 2014.PubMed/NCBI View Article : Google Scholar
26	Guo S, Bai R, Liu W, Zhao A, Zhao Z, Wang Y, Wang Y, Zhao W and Wang W: miR-22 inhibits osteosarcoma cell proliferation and migration by targeting HMGB1 and inhibiting HMGB1-mediated autophagy. Tumour Biol. 35:7025–7034. 2014.PubMed/NCBI View Article : Google Scholar
27	Jiang D, Wang H, Li Z, Li Z, Chen X and Cai H: MiR-142 inhibits the development of cervical cancer by targeting HMGB1. Oncotarget. 8:4001–4007. 2017.PubMed/NCBI View Article : Google Scholar
28	Xia J, Yu X, Song X, Li G, Mao X and Zhang Y: Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells. Mol Med Rep. 15:488–494. 2017.PubMed/NCBI View Article : Google Scholar
29	Lee HJ, Kim A, Song IH, Park IA, Yu JH, Ahn JH and Gong G: Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in breast cancer. Pathol Int. 66:202–209. 2016.PubMed/NCBI View Article : Google Scholar
30	Zhou RR, Zhao SS, Zou MX, Zhang P, Zhang BX, Dai XH, Li N, Liu HB, Wang H and Fan XG: HMGB1 cytoplasmic translocation in patients with acute liver failure. BMC Gastroenterol. 11(21)2011.PubMed/NCBI View Article : Google Scholar